Drugs / FH FOLR1 ST CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07227571 | Jan 2026 → Jan 2044 expected | osteosarcoma | Fred Hutchinson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FH FOLR1 ST CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07227571 ↗ |
| Modality | Cell therapy | “CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they attack tumor cells.” NCT07227571 ↗ |
| Route | Intravenous | “given to the patient by an intravenous infusion” NCT07227571 ↗ |
| Target | FOLR1 | “Then the gene for a special receptor that binds to a certain protein on the patient's tumor cells, such as FOLR1, is added to the T cells in the laboratory.” NCT07227571 ↗ |